On January 8, 2024, Kazia Therapeutics Limited?s Board of Directors appointed Gabrielle Heaton as its Principal Accounting Officer and Principal Financial Officer, effective January 15, 2024. Ms. Krumeich will remain with the Company in an advisory role for a period of time to be mutually agreed between her and the Company to support the transition. Ms. Heaton currently serves as the Company?s Vice President of Finance and Administration.

She has over 20 years of commercial experience in healthcare and biotech for multinational, ASX listed and overseas companies. She has held several senior Finance positions including CFO, Quality Auditor and been responsible for Human Resources and IT. Ms. Heaton has a Bachelor of Business from the University of Technology and is a member of CPA Australia.